NEWARK, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced presentations of preclinical data from ongoing studies of Rain’s lead candidate, tarloxotinib, at the American Association for Cancer Research (AACR) Annual Meeting 2019 being held March 29-April 3, 2019 in Atlanta, Georgia. Poster presentations will feature data detailing in vitro activity of tarloxotinib for a variety of EGFR/ HER2 mutations and in vitro and in vivo efficacy in NRG1 altered cancers, as well as data demonstrating that STEAP4 expression can serve as an additional biomarker to predict sensitivity to tarloxotinib therapy in upcoming clinical trials.
Details on the presentations are as follows:
Presentation Title: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers
Presenter: Vijaya Tirunagaru, Ph.D, Rain Therapeutics
Poster Session Date and Time: Monday, April 1, 2019, 1:00 p.m. – 5:00 p.m. EDT
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 15
Presentation Title: Potent in vitro activity of Tarloxotinib for EGFR C797S and other mutations refractory to current EGFR tyrosine kinase inhibitors
Presenter: Kenichi Suda, M.D., Kindai University Faculty of Medicine
Poster Session Date and Time: Monday, April 1, 1:00 p.m. – 5:00 p.m. EDT
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 15
Presentation Title: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers
Presenter: Vijaya Tirunagaru, Ph.D, Rain Therapeutics
Poster Session Date and Time: Tuesday, April 2, 2019, 1:00 p.m. – 5:00 p.m. EDT
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 21
Additional details can be found on the conference website. A copy of presentation materials can be accessed by visiting the Science and Publications section of the Rain Therapeutics website after the presentations conclude.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib. For more information, visit www.rainthera.com
Media Contact
Cait Williamson, Ph.D.
LifeSci Public Relations
+1.646.751.4366
cait@lifescipublicrelations.com